FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to the use of thrombin. The use of thrombin at a concentration of 50 NM per 50 thousand cells is proposed for reduction in inflammation with diabetes mellitus on the background of hyperglycemia on an in vitro model.
EFFECT: above-described invention allows for effective reduction in inflammation with diabetes mellitus on the background of hyperglycemia on an in vitro model.
1 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING COMPLEX PROTECTION OF CELLS UNDER NEURO-INFLAMMATORY ON IN VITRO MODELS UNDER EXPOSURE TO PAR1 AGONIST | 2022 |
|
RU2796524C1 |
| PREPARATION POSSESSING NEUROPROTECTIVE PROPERTIES IN EXPERIMENT AND METHOD OF OBTAINING THEREOF | 2015 |
|
RU2614694C1 |
| COMPOSITION CONTAINING EXTRACT OR FRACTION FROM JUSTICIA PLANT | 2015 |
|
RU2671501C1 |
| AGENT FOR ANTIPLATELET, ANTI-INFLAMMATORY AND CYTOPROTECTIVE THERAPY | 2012 |
|
RU2483746C1 |
| METHOD FOR NEUROPROTECTION IN EXPERIMENT | 2015 |
|
RU2616509C1 |
| METHOD FOR DETERMINING FUNCTIONAL ACTIVITY PROFILE OF RECEPTOR PEPTIDES-AGONISTS ACTIVATED BY PROTEASE TYPE 1 UNDER EXPERIMENTAL CONDITIONS IMITATING ISCHEMIC | 2020 |
|
RU2750893C1 |
| PYRIDAZINE[4',5':3,4]PYRROLO[2,1-a]ISOQUINOLINE DERIVATIVES AND THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS WITH ACIDS AND COMPLEXING AGENTS | 1994 |
|
RU2138499C1 |
| FcγRIIB RECEPTOR ANTIBODIES AND APPLICATION THEREOF | 2005 |
|
RU2404991C2 |
| METHOD OF INDUCING TARGETED DIFFERENTIATION OF MULTIPOTENT PROGENITOR CELLS OF PANCREAS IN INSULIN-PRODUCING BETA CELLS DURING DIABETES | 2014 |
|
RU2579997C2 |
| LACTOBACILLUS CRISPATUS KBL693 STRAIN AND ITS APPLICATION | 2019 |
|
RU2791561C2 |
